Yuki Fujiwara
Concepts (310)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 25 | 2025 | 1544 | 1.860 |
Why?
| | B7-H1 Antigen | 13 | 2025 | 217 | 1.640 |
Why?
| | Macrophage Activation | 8 | 2025 | 201 | 1.190 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2024 | 220 | 0.990 |
Why?
| | Tumor Microenvironment | 14 | 2025 | 672 | 0.940 |
Why?
| | Immunity | 3 | 2021 | 144 | 0.870 |
Why?
| | Sialic Acid Binding Ig-like Lectin 1 | 3 | 2025 | 4 | 0.860 |
Why?
| | Cell Line, Tumor | 20 | 2025 | 3406 | 0.740 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2123 | 0.730 |
Why?
| | Mice | 40 | 2025 | 17759 | 0.720 |
Why?
| | Immunotherapy | 8 | 2025 | 640 | 0.710 |
Why?
| | Liver Neoplasms | 5 | 2024 | 785 | 0.640 |
Why?
| | Neoplasms | 7 | 2025 | 2643 | 0.640 |
Why?
| | Immunologic Factors | 2 | 2018 | 236 | 0.640 |
Why?
| | Atherosclerosis | 4 | 2024 | 415 | 0.630 |
Why?
| | Flavanones | 2 | 2022 | 7 | 0.620 |
Why?
| | Chemokine CXCL10 | 3 | 2024 | 39 | 0.600 |
Why?
| | Hepatoblastoma | 3 | 2024 | 46 | 0.600 |
Why?
| | Thalidomide | 1 | 2018 | 40 | 0.590 |
Why?
| | Orosomucoid | 3 | 2025 | 9 | 0.590 |
Why?
| | Diosgenin | 1 | 2018 | 1 | 0.580 |
Why?
| | Saponins | 1 | 2018 | 8 | 0.570 |
Why?
| | Lymph Nodes | 5 | 2025 | 492 | 0.570 |
Why?
| | Immunomodulation | 1 | 2018 | 98 | 0.560 |
Why?
| | Hyaluronan Receptors | 1 | 2018 | 103 | 0.550 |
Why?
| | Animals | 44 | 2025 | 36850 | 0.540 |
Why?
| | Cell Proliferation | 13 | 2025 | 2476 | 0.540 |
Why?
| | Colonic Neoplasms | 4 | 2024 | 256 | 0.530 |
Why?
| | Carcinoma, Renal Cell | 3 | 2025 | 215 | 0.520 |
Why?
| | Breast Neoplasms | 4 | 2023 | 2234 | 0.510 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 153 | 0.510 |
Why?
| | Lung Neoplasms | 7 | 2025 | 2489 | 0.510 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2025 | 250 | 0.490 |
Why?
| | Kidney Neoplasms | 3 | 2025 | 401 | 0.450 |
Why?
| | Foam Cells | 4 | 2022 | 18 | 0.440 |
Why?
| | Glycation End Products, Advanced | 3 | 2020 | 82 | 0.440 |
Why?
| | Cell Communication | 5 | 2023 | 315 | 0.410 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1993 | 0.400 |
Why?
| | Colorectal Neoplasms | 4 | 2024 | 791 | 0.400 |
Why?
| | Membrane Glycoproteins | 2 | 2025 | 500 | 0.390 |
Why?
| | Tomatine | 1 | 2012 | 1 | 0.390 |
Why?
| | Sterol O-Acyltransferase | 1 | 2012 | 5 | 0.380 |
Why?
| | Hyperlipidemias | 2 | 2014 | 120 | 0.380 |
Why?
| | Apolipoproteins E | 1 | 2012 | 83 | 0.370 |
Why?
| | Macrophages, Peritoneal | 2 | 2024 | 94 | 0.370 |
Why?
| | Mice, Inbred C57BL | 14 | 2025 | 5750 | 0.360 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 57 | 0.350 |
Why?
| | Down-Regulation | 2 | 2017 | 656 | 0.340 |
Why?
| | Aorta | 3 | 2024 | 417 | 0.330 |
Why?
| | Plant Extracts | 1 | 2012 | 202 | 0.330 |
Why?
| | Melanoma, Experimental | 2 | 2022 | 114 | 0.320 |
Why?
| | STAT3 Transcription Factor | 4 | 2023 | 206 | 0.310 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2023 | 95 | 0.310 |
Why?
| | Mice, Knockout | 7 | 2025 | 3009 | 0.300 |
Why?
| | Ligands | 4 | 2025 | 661 | 0.290 |
Why?
| | Anti-Inflammatory Agents | 2 | 2024 | 496 | 0.290 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2025 | 209 | 0.280 |
Why?
| | Humans | 47 | 2025 | 136803 | 0.280 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2024 | 683 | 0.280 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1095 | 0.270 |
Why?
| | Thiophenes | 2 | 2019 | 117 | 0.270 |
Why?
| | Neoplastic Syndromes, Hereditary | 2 | 2024 | 44 | 0.260 |
Why?
| | Brain Neoplasms | 3 | 2025 | 1235 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1396 | 0.250 |
Why?
| | Interferon-alpha | 2 | 2025 | 198 | 0.250 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2025 | 15 | 0.240 |
Why?
| | Thyroid Nuclear Factor 1 | 1 | 2025 | 16 | 0.240 |
Why?
| | Mice, Inbred BALB C | 3 | 2025 | 1269 | 0.240 |
Why?
| | Chondrosarcoma | 1 | 2025 | 17 | 0.240 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2025 | 10 | 0.240 |
Why?
| | Interleukins | 2 | 2025 | 251 | 0.240 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 60 | 0.230 |
Why?
| | Pancreatic Neoplasms | 2 | 2025 | 935 | 0.230 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 152 | 0.230 |
Why?
| | Interleukin-10 | 3 | 2021 | 302 | 0.220 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2024 | 19 | 0.220 |
Why?
| | Carcinoma, Embryonal | 1 | 2023 | 3 | 0.220 |
Why?
| | Photochemotherapy | 1 | 2024 | 37 | 0.220 |
Why?
| | Neuroendocrine Tumors | 1 | 2025 | 116 | 0.210 |
Why?
| | Disease Models, Animal | 8 | 2025 | 4282 | 0.210 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 1076 | 0.210 |
Why?
| | Clodronic Acid | 1 | 2023 | 17 | 0.210 |
Why?
| | Immunohistochemistry | 2 | 2025 | 1733 | 0.210 |
Why?
| | Aortic Diseases | 1 | 2024 | 117 | 0.210 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 800 | 0.200 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 197 | 0.200 |
Why?
| | Neovascularization, Pathologic | 1 | 2025 | 301 | 0.200 |
Why?
| | Phenotype | 4 | 2025 | 3189 | 0.200 |
Why?
| | beta-Cyclodextrins | 1 | 2023 | 28 | 0.200 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2020 | 109 | 0.200 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2023 | 66 | 0.200 |
Why?
| | Cholangiocarcinoma | 1 | 2024 | 104 | 0.200 |
Why?
| | Chemokine CXCL13 | 1 | 2022 | 8 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2025 | 248 | 0.200 |
Why?
| | Interleukin-6 | 3 | 2023 | 778 | 0.200 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2022 | 11 | 0.190 |
Why?
| | Bile Duct Neoplasms | 1 | 2024 | 123 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 77 | 0.190 |
Why?
| | Signal Transduction | 8 | 2024 | 5077 | 0.190 |
Why?
| | Cisplatin | 1 | 2024 | 320 | 0.190 |
Why?
| | Testicular Neoplasms | 1 | 2023 | 110 | 0.190 |
Why?
| | Immune System Diseases | 1 | 2022 | 39 | 0.190 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.190 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 27 | 0.190 |
Why?
| | Sulfur Compounds | 1 | 2021 | 7 | 0.190 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2021 | 16 | 0.180 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 2 | 2020 | 61 | 0.180 |
Why?
| | Osteopontin | 1 | 2021 | 33 | 0.180 |
Why?
| | CD47 Antigen | 1 | 2021 | 38 | 0.180 |
Why?
| | Cell Line | 5 | 2024 | 2838 | 0.180 |
Why?
| | Interleukin-12 | 2 | 2022 | 121 | 0.180 |
Why?
| | Antigens, CD | 3 | 2020 | 521 | 0.180 |
Why?
| | Neuropeptides | 1 | 2021 | 73 | 0.180 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2022 | 137 | 0.180 |
Why?
| | Glioblastoma | 1 | 2025 | 343 | 0.180 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 321 | 0.180 |
Why?
| | Phagocytes | 1 | 2021 | 100 | 0.170 |
Why?
| | Mouth Neoplasms | 1 | 2022 | 120 | 0.170 |
Why?
| | Burns, Electric | 1 | 2020 | 26 | 0.170 |
Why?
| | Penicillium | 1 | 2020 | 6 | 0.170 |
Why?
| | Immune Tolerance | 1 | 2023 | 362 | 0.170 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2021 | 80 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 361 | 0.170 |
Why?
| | Protective Agents | 1 | 2020 | 41 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2024 | 528 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1242 | 0.160 |
Why?
| | Receptors, Cell Surface | 2 | 2020 | 382 | 0.160 |
Why?
| | Osteoblasts | 1 | 2020 | 126 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 179 | 0.160 |
Why?
| | Female | 17 | 2025 | 72816 | 0.150 |
Why?
| | Oxadiazoles | 1 | 2019 | 33 | 0.150 |
Why?
| | HEK293 Cells | 1 | 2021 | 729 | 0.150 |
Why?
| | Collagen Type I | 1 | 2019 | 133 | 0.150 |
Why?
| | Kupffer Cells | 1 | 2018 | 50 | 0.150 |
Why?
| | Hepatitis | 1 | 2018 | 48 | 0.150 |
Why?
| | Aging | 3 | 2025 | 1864 | 0.150 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 657 | 0.150 |
Why?
| | Cholesterol Esters | 2 | 2022 | 8 | 0.140 |
Why?
| | Aortitis | 1 | 2018 | 10 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2021 | 1163 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 225 | 0.140 |
Why?
| | Disease Progression | 6 | 2024 | 2751 | 0.140 |
Why?
| | Arginine | 1 | 2019 | 271 | 0.140 |
Why?
| | Transcriptome | 1 | 2024 | 969 | 0.140 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2023 | 173 | 0.140 |
Why?
| | Interferon Type I | 1 | 2018 | 141 | 0.140 |
Why?
| | Single-Chain Antibodies | 1 | 2017 | 18 | 0.140 |
Why?
| | Pyridinium Compounds | 1 | 2017 | 26 | 0.140 |
Why?
| | Neoplasm Transplantation | 3 | 2024 | 257 | 0.140 |
Why?
| | Lysine | 1 | 2019 | 294 | 0.130 |
Why?
| | Mutation | 2 | 2025 | 3947 | 0.130 |
Why?
| | Sulfoxides | 1 | 2016 | 3 | 0.130 |
Why?
| | Lycopodium | 1 | 2016 | 1 | 0.130 |
Why?
| | Sepsis | 1 | 2022 | 614 | 0.130 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 20 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 2018 | 425 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2020 | 407 | 0.120 |
Why?
| | Apoptosis | 3 | 2020 | 2552 | 0.120 |
Why?
| | Lymphoma | 1 | 2017 | 208 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 371 | 0.120 |
Why?
| | Sarcoma | 1 | 2018 | 188 | 0.120 |
Why?
| | Levofloxacin | 1 | 2015 | 27 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 604 | 0.120 |
Why?
| | Male | 17 | 2025 | 67330 | 0.120 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 88 | 0.120 |
Why?
| | Toll-Like Receptor 4 | 2 | 2021 | 273 | 0.120 |
Why?
| | Quinolines | 1 | 2016 | 177 | 0.110 |
Why?
| | Liver | 2 | 2020 | 1940 | 0.110 |
Why?
| | Melanoma | 1 | 2022 | 757 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 852 | 0.110 |
Why?
| | Helicobacter Infections | 1 | 2014 | 32 | 0.110 |
Why?
| | Helicobacter pylori | 1 | 2014 | 42 | 0.110 |
Why?
| | Lung | 2 | 2025 | 4063 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2020 | 938 | 0.100 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1272 | 0.100 |
Why?
| | Cells, Cultured | 4 | 2024 | 4192 | 0.100 |
Why?
| | Mice, Knockout, ApoE | 2 | 2024 | 11 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2015 | 287 | 0.090 |
Why?
| | Hydrogels | 1 | 2019 | 674 | 0.090 |
Why?
| | Cricetinae | 1 | 2012 | 289 | 0.090 |
Why?
| | Scavenger Receptors, Class A | 1 | 2011 | 12 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1772 | 0.090 |
Why?
| | Prognosis | 3 | 2025 | 4013 | 0.090 |
Why?
| | Mannose | 2 | 2023 | 24 | 0.090 |
Why?
| | Antibodies | 2 | 2023 | 411 | 0.090 |
Why?
| | Cytokines | 4 | 2023 | 2084 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 562 | 0.080 |
Why?
| | Lymphocyte Activation | 2 | 2025 | 1150 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2023 | 613 | 0.080 |
Why?
| | Coculture Techniques | 2 | 2021 | 239 | 0.080 |
Why?
| | Influenza, Human | 1 | 2015 | 618 | 0.080 |
Why?
| | Reactive Oxygen Species | 2 | 2024 | 621 | 0.070 |
Why?
| | Cell Movement | 2 | 2022 | 968 | 0.070 |
Why?
| | Structure-Activity Relationship | 2 | 2020 | 570 | 0.070 |
Why?
| | Mice, Inbred ICR | 2 | 2018 | 119 | 0.070 |
Why?
| | Molecular Structure | 2 | 2020 | 489 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2025 | 2163 | 0.060 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 1 | 2025 | 2 | 0.060 |
Why?
| | Cell Dedifferentiation | 1 | 2025 | 32 | 0.060 |
Why?
| | Monocytes | 2 | 2021 | 563 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2021 | 789 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1798 | 0.060 |
Why?
| | Middle Aged | 5 | 2025 | 33239 | 0.060 |
Why?
| | Bevacizumab | 1 | 2025 | 135 | 0.060 |
Why?
| | Mesentery | 1 | 2024 | 48 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2052 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 138 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2025 | 226 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2024 | 78 | 0.050 |
Why?
| | Survival Rate | 2 | 2020 | 1964 | 0.050 |
Why?
| | Aged | 4 | 2025 | 23808 | 0.050 |
Why?
| | Cytoplasm | 1 | 2024 | 272 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2024 | 287 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2024 | 810 | 0.050 |
Why?
| | Denervation | 1 | 2022 | 24 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 49 | 0.050 |
Why?
| | Lipocalin-2 | 1 | 2022 | 79 | 0.050 |
Why?
| | Scavenger Receptors, Class B | 1 | 2022 | 14 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 868 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 813 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 184 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2024 | 234 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 110 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 2105 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2021 | 124 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 241 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 2021 | 269 | 0.040 |
Why?
| | Blotting, Western | 1 | 2023 | 1225 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2024 | 434 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 32 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 366 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 309 | 0.040 |
Why?
| | Mice, Nude | 1 | 2022 | 696 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2021 | 148 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2021 | 216 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2020 | 163 | 0.040 |
Why?
| | Hepatocytes | 1 | 2021 | 220 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 410 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 190 | 0.040 |
Why?
| | Inflammation | 3 | 2019 | 2835 | 0.040 |
Why?
| | Endoribonucleases | 1 | 2020 | 80 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 217 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2025 | 846 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 285 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 379 | 0.040 |
Why?
| | Glycosylation | 1 | 2019 | 151 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 389 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 163 | 0.040 |
Why?
| | Neutrophils | 2 | 2015 | 1236 | 0.040 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2020 | 179 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 278 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2018 | 50 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 372 | 0.040 |
Why?
| | Survival Analysis | 1 | 2022 | 1321 | 0.040 |
Why?
| | Fibrin | 1 | 2019 | 81 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1430 | 0.040 |
Why?
| | Doxorubicin | 1 | 2020 | 362 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 75 | 0.040 |
Why?
| | Serum Albumin | 1 | 2018 | 150 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 543 | 0.040 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 253 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2486 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 403 | 0.030 |
Why?
| | Tyrphostins | 1 | 2017 | 18 | 0.030 |
Why?
| | Peptide Library | 1 | 2017 | 88 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1231 | 0.030 |
Why?
| | Chemokine CCL4 | 1 | 2017 | 23 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 305 | 0.030 |
Why?
| | Protein Stability | 1 | 2017 | 176 | 0.030 |
Why?
| | Necrosis | 1 | 2018 | 245 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 43 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 191 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3286 | 0.030 |
Why?
| | Caspase 3 | 1 | 2017 | 246 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 289 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 778 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 888 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 417 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 446 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2216 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1350 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2015 | 51 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 552 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1496 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 513 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2015 | 184 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5639 | 0.030 |
Why?
| | Influenza A virus | 1 | 2015 | 110 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2014 | 47 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2138 | 0.030 |
Why?
| | Pyridines | 1 | 2017 | 506 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 204 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2014 | 190 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2014 | 337 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1710 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 7593 | 0.020 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2011 | 16 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4145 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2664 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2011 | 183 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 915 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2605 | 0.020 |
Why?
| | Shock, Septic | 1 | 2011 | 219 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2015 | 1314 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2878 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 617 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 886 | 0.020 |
Why?
| | NF-kappa B | 1 | 2011 | 691 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2014 | 1982 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 15510 | 0.010 |
Why?
|
|
Fujiwara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|